With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market has been taking off. The LN arena is especially busy now with two competitors gaining steam, but SLE is also on physicians’ minds with the potential for CAR-T cell therapy treatment on the horizon, according to research from Spherix Global Insights.
Lupus Therapeutics, a clinical research affiliate of the Lupus Research Alliance, inked a partnership deal with AbbVie to help run phase 3 trials of the drugmaker’s upadacitinib in systemic lupus erythematosus (SLE).
NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announces a partnership with AbbVie Inc. for the Phase 3 clinical program of upadacitinib (RINVOQ®) in individuals living with systemic lupus erythematosus (SLE). In this partnership, Lupus Therapeutics will assist with study participant recruitment, site activation and engagement efforts through the Lupus Clinical Investigators Network (LuCIN) of top academic centers throughout North America.
NEW YORK, June 2, 2023 /PRNewswire/ -- Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
NEW YORK, April 20, 2023 /PRNewswire/ -- The Lupus Research Alliance (LRA) today announced the newest Lupus Mechanisms and Targets Award grant recipients. The winning four projects collectively test potential treatment approaches to prevent lupus from developing or reducing lupus disease activity. Lupus has a broad range of causes and symptoms, and these multiple approaches are important for designing customized therapies that can provide better outcomes for a wide range of patients.
he Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a ...
WASHINGTON, Jan. 22, 2021 /PRNewswire/ -- For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy regimen. Today, Aurinia Pharmaceuticals announced they received authorization from the FDA to market Lupkynis™ (voclosporin), a first-ever oral therapy for lupus nephritis that blocks a protein in the immune system called calcineurin. The company previously had reported positive data from a late-stage clinical study that demonstrated Lupkynis was superior to standard of care for treating lupus nephritis.
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals' LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month.
PPD, Inc. and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance have entered into a collaboration to expand and enhance lupus clinical research for PPD’s pharmaceutical and biotech customers.
PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, and Lupus Therapeutics (LT), an affiliate of the Lupus Research Alliance known for its lupus clinical trials expertise, have entered into a collaboration to expand and enhance lupus clinical research for PPD’s pharmaceutical and biotech customers.